 "Ipca Labs arm acquires 80% stake in US-based Bayshore Pharma for $10.286 mn")
Mumbai-based pharma company Ipca Labs on Wednesday said its subsidiary Ipca Pharmaceuticals Inc, USA, had acquired 80 per cent share capital of New Jersey-headquartered generic drug major Bayshore Pharmaceuticals Llc for $10.286 million.
“The company's wholly-owned subsidiary, Ipca Pharmaceuticals Inc, USA, has acquired, on 2 October, 2018, 80 per cent share capital of Bayshore Pharmaceuticals LLC, a New Jersey limited liability company @ $10.286 millions,” Ipca Labs informed stock exchanges in a statement.
Bayshore had reported a total income of $7.05 million and earnings before interest, depreciation tax and amortisation (Ebidta) of $0.56 million, for the year ended December 31, 2017.
The acquisition of a majority stake in Bayshore will allow the company to commercialise its registered generic drug products in the US market.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%